Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Chinese Finance Ministry Funding For Healthcare Reforms Reflects Boost Slated For 2011

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - One week after China's Ministry Of Health unveiled its new five year plan for reforms in public hospitals, the Ministry Of Finance announced Nov. 18 that the central government has allocated RMB 12.3 billion ($1.85 billion) to support local healthcare reforms

You may also be interested in...

China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home

SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets

Chinese Government Faces Setback In Pledged $124 Billion In Funding For Health System Reforms

SHANGHAI - The Chinese government's sweeping health system reforms, set to be launched in stages over the next decade, are facing significant funding setbacks, according to an analyst who has been closely monitoring the process

China Issues Three-year Healthcare Reform Plan To Invest RMB 850 Billion

SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts